Oral Insulin

• Product Class: Protein

• Indication: Type I and II Diabetes

• Partnership Status: Discussions ongoing with major Pharma

• Development Status: Phase II studies ongoing

• CY02 Accomplishments: Euglycemic Clamp Study completed; 90-day toxicology studies completed; fed/fast study ongoing

• Upcoming CY02 Milestones: Development of tablet formulation; Presentation of Phase I data at American Diabetes Association 6/16/02

Previous slide

Next slide

Back to first slide

View graphic version